OBJECTIVE: We aimed to show the relationship between paraoxonase 1 (PON1) gene polymorphism and the development of prostate cancer (PCa). MATERIAL AND METHODS: We investigated the association of single nuclotide polymorphisms of PON1 enzyme with the development of PCa risk. A total of 147 male patients were divided into PCa, and control groups. The control group was also divided into two subgroups according to serum prostate specific antigen (PSA) levels as non PCa-high PSA (>4 ng/mL) and non PCa-low PSA (≤4 ng/mL) groups. RESULTS: The mean ages of the patients were 64.81 years, 63.27 years and 64.22 years in PCa group, non PCa-low PSA and non PCa -high PSA groups, respectively. The mean PSA levels were 10.9 ng/mL, 1.16 ng/mL and 6.63 ng/mL for PCa group, non PCa -low PSA and non PCa -high PSA groups, respectively. In terms of PON1 polymorphisms and allele frequencies, there were no statistically significant differences between PCa and control groups. There was not a statistically significant difference between PCa and non PCa-high PSA groups as for genotypic and allelic frequencies. As a result of this small sample sized hypothetical study of polymorphism, a relationship could not be detected between PCa development and PON1 gene polymorphism. CONCLUSION: According to the results of this preliminary study, it is thought that more comprehensive future studies are necessary to clarify the possible role of PON1 gene polymorphism in the etiology of PCa.
OBJECTIVE: We aimed to show the relationship between paraoxonase 1 (PON1) gene polymorphism and the development of prostate cancer (PCa). MATERIAL AND METHODS: We investigated the association of single nuclotide polymorphisms of PON1 enzyme with the development of PCa risk. A total of 147 male patients were divided into PCa, and control groups. The control group was also divided into two subgroups according to serum prostate specific antigen (PSA) levels as non PCa-high PSA (>4 ng/mL) and non PCa-low PSA (≤4 ng/mL) groups. RESULTS: The mean ages of the patients were 64.81 years, 63.27 years and 64.22 years in PCa group, non PCa-low PSA and non PCa -high PSA groups, respectively. The mean PSA levels were 10.9 ng/mL, 1.16 ng/mL and 6.63 ng/mL for PCa group, non PCa -low PSA and non PCa -high PSA groups, respectively. In terms of PON1 polymorphisms and allele frequencies, there were no statistically significant differences between PCa and control groups. There was not a statistically significant difference between PCa and non PCa-high PSA groups as for genotypic and allelic frequencies. As a result of this small sample sized hypothetical study of polymorphism, a relationship could not be detected between PCa development and PON1 gene polymorphism. CONCLUSION: According to the results of this preliminary study, it is thought that more comprehensive future studies are necessary to clarify the possible role of PON1 gene polymorphism in the etiology of PCa.
Authors: Chen Mao; Li-Xin Qiu; Ping Zhan; Kai Xue; Hong Ding; Fang-Bing Du; Jin Li; Qing Chen Journal: J Cancer Res Clin Oncol Date: 2009-12-10 Impact factor: 4.553
Authors: Kathryn Hughes Barry; Lee E Moore; Linda M Liao; Wen-Yi Huang; Gabriella Andreotti; Matthew Poulin; Sonja I Berndt Journal: Prostate Date: 2015-08-07 Impact factor: 4.104
Authors: Galina Lurie; Lynne R Wilkens; Pamela J Thompson; Katharine E McDuffie; Michael E Carney; Keith Y Terada; Marc T Goodman Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-08 Impact factor: 4.254
Authors: Susan Searles Nielsen; Beth A Mueller; Anneclaire J De Roos; Hannah-Malia A Viernes; Federico M Farin; Harvey Checkoway Journal: Environ Health Perspect Date: 2005-07 Impact factor: 9.031